A 2005 randomized trial showed that patients with methylated MGMT promoters had a greater survival benefit than patients with unmethylated MGMT promoters in glioblastoma patients treated with combination radiotherapy and temozolomide chemotherapy (Hegi et al., 2005). This evidence concerns the gene MGMT and glioblastoma.